At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
bortezomib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
VELCADE (Bortezomib) and Thalidomide in Newly Diagnosed Patients With Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Feb 7, 2006·Updated Mar 1, 2018
In Brief
A Phase 2 clinical trial evaluating bortezomib and thalidomide for Multiple Myeloma. Completed, enrolled 30 participants across 1 site.
Detailed Summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Giving bortezomib together with thalidomide may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with thalidomide works in treating patients with newly diagnosed stage II or stage III multiple myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2004
First PostedFeb 2006
Primary CompletionNov 2010
TodayJul 2026
First PostedFeb 7, 2006
Enrollment StartSep 1, 2004
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 20.4 years ago
Interventions
bortezomibdrug
thalidomidedrug